ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Wade Iams shares his insights on connecting actionable mutations to therapy in lung cancer (Video 3/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Wade Iams shares his insights on connecting actionable mutations to therapy in lung cancer (Video 3/3)

    Published May 12, 2025

    W

    Wade Iams, MD

    Medical Professional

    PM in Lung – matching therapy to mutation

    More in this series: Precision Medicine Lung + NGS_2025
    Dr. Wade Iams shares his insights on liquid and tissue-based NGS testing in lung cancer (Video 1/3)

    Dr. Wade Iams shares his insights on liquid and tissue-based NGS testing in lung cancer (Video 1/3)

    Liquid NGS background

    Wade Iams, MD
    Lung Cancer
    Dr. Wade Iams shares his insights on reading an NGS report in lung cancer (Video 2/3)

    Dr. Wade Iams shares his insights on reading an NGS report in lung cancer (Video 2/3)

    Reading an NGS report

    Wade Iams, MD
    Lung Cancer
    Related Videos
    What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)

    What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)

    Rahul Banerjee, MD
    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Eytan Stein, MD
    Dr. Wade Iams discusses adverse event prophylaxis strategies for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 1/3)

    Dr. Wade Iams discusses adverse event prophylaxis strategies for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 1/3)

    Wade Iams, MD
    What makes ropeginterferon a modern interferon? Dr. Gabriela Hobbs explains. (Video 1/3)

    What makes ropeginterferon a modern interferon? Dr. Gabriela Hobbs explains. (Video 1/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)

    Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)

    Eytan Stein, MD